 |
 |
 |
|
|
|
ABOUT US
The consortium approach accelerates the development process of the applications through the provision of intellectual support, ensuring that the development approaches adopted are continuously focused keenly upon the end application goal and generating the necessary records of development to meet the most stringent needs of later commercialisation partners, which are required to take the technology to full commercialisation in the market place.
Experience has shown that by defining measurable objectives and setting realistic schedules, building joint teams in a consortium and, above all, anticipating and mitigating risks and opportunities – in short, a highly structured development approach - improves the chances of rapid commercialisation success. Motivation and commitment from the consortium, with the added synergy of knowledge and experience, achieves cooperative results and tangible, lasting successes. In doing so, Swedish Biomimetics 3000® is taking on tasks normally not addressed by traditional Venture Capital Groups, Bioincubators, Spin-outs, or Governments.
The V²IO® model is conceived as a much needed complement not only for technology advancements by traditional funding bodies but also as a successful alternative for established Corporations to find innovations outside their own organizations². Swedish Biomimetics 3000® has the vision, commitment and the necessary virtual global network to actively drive scientific, financial and commercial growth initiatives, thereby accelerating technology portfolios.
Read more  |
|
 |
|
 |
|
 |
|
